Latest Asx Listing News

Nexion Group has agreed to sell its telecommunications subsidiaries for $4.1 million, aiming to reduce debt and pivot towards its high-growth AI and business intelligence operations.

ARC Funds Limited posted a $2.45 million loss for FY2025, driven by strategic investments and increased transaction costs as it expands its funds management platform.

DigiCo Infrastructure REIT confirms its FY25 EBITDA slightly exceeded IPO guidance and aligned with analyst forecasts, attributing recent share price declines to the absence of FY26 earnings guidance.

Helix Resources Limited’s HLXOA securities have been suspended from trading pending regulatory compliance, raising questions about the company’s immediate outlook.

Sequoia Financial Group reported a 13.7% rise in operating profit for FY25, driven by significant growth in funds under advice and operational efficiencies. The company declared a fully franked final dividend, signaling confidence despite ongoing regulatory investigations.

Austral Gold Limited reported a net loss of US$1.3 million for the first half of 2025, while completing refurbishment of its Casposo plant to diversify production. Despite operational challenges and increased costs, the company leans on shareholder support and strategic investments to manage liquidity pressures.

Hartshead Resources has voluntarily suspended trading on the ASX pending a significant announcement about a well carry agreement linked to its P2607 Licence. The suspension is set to last until the announcement or early September.

Terra Metals has raised $15 million through an institutional placement led by cornerstone investors to fast-track exploration and development at its polymetallic Dante Project in Western Australia.

Greatland Resources Limited has reported a robust unaudited FY2025 result, generating $337.3 million net profit after tax from seven months of Telfer gold-copper mine operations, alongside a successful ASX listing and strong cash flow.

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.

Pengana Capital Group reported a strong turnaround in FY 2025 profitability, driven by a surge in private credit funds under management and successful new product launches. The firm’s strategic shift towards private markets is reshaping its revenue profile and balance sheet strength.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.